Is Continuous Subcutaneous Insulin the Best Approach for Children with Type 1 Diabetes?

Not as initial therapy during the year after diagnosis, based on a randomized, controlled trial

Use of continuous subcutaneous insulin (CSII) for initial treatment of children with type 1 diabetes mellitus (T1DM) has doubled in the United Kingdom over the past 10 years. Yet efficacy data on this expensive therapy are still limited.

In a multicenter, randomized, controlled trial, investigators assessed the clinical efficacy and cost of CSII compared with multiple daily injections (MDI) in 293 children with newly diagnosed T1DM in the U.K. Participants were aged 7 months to 15 years (mean age, 10 years).

After 12 months, mean glycated hemoglobin A_1c (HbA_1c) level was similar between groups (60.9 mmol/mol in the CSII group and 58.5 mmol/mol in the MDI group). These mean HbA_1c levels did not meet the recommended target of <48 mmol/mol set b…

Reviewing Author

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

Is Continuous Subcutaneous Insulin the Best Approach for Children with Type 1 Diabetes?

Topics

Reviewing Author